KPF
LKFT

K2 Principal Fund’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

K2 Principal Fund’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,500
Closed -$235K – 275
2022
Q3 		$235K Buy
+5,500
New +$282K 0.03% 176

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

K2 Principal Fund's LKFT Position: Q4 2022 in Review

K2 Principal Fund sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 5,500 shares — an estimated $235K sold.

K2 Principal Fund first reported a position in LKFT in Q3 2022 and held it in 1 quarter. The position peaked at $235K in Q3 2022. 75 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

  • K2 Principal Fund reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
  • K2 Principal Fund sold 5,500 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $235K.
  • K2 Principal Fund first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2022 and held it in 1 quarter.
  • K2 Principal Fund's Lakefront Biotherapeutics American Depositary Shares position peaked at $235K in Q3 2022.
  • 75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on K2 Principal Fund's 13F filing for Q4 2022, filed 10 Feb 2023.